Is Retatrutide the Same as “GLP-3”? What the Term Actually Means

If you’ve seen research peptide vendors refer to “GLP-3” or “GLP-3RT,” you may be wondering whether that’s a different compound from Retatrutide — it isn’t. Here’s the clarification.

“GLP-3” is not an official receptor classification

Retatrutide is a triple receptor agonist, acting on the GLP-1, GIP, and glucagon (GCGR) receptor pathways. “GLP-3” is informal shorthand some vendors and researchers use to describe this triple-agonist mechanism — it is not a distinct fourth incretin hormone or an official pharmacological classification. When you see “GLP-3,” “GLP-3RT,” or “Reta GLP-3” used to describe a product, it is referring to Retatrutide.

Why the terminology exists

Retatrutide’s triple-receptor mechanism is a step beyond dual GLP-1/GIP agonists like tirzepatide, and “GLP-3” shorthand emerged informally in research and online communities to describe that added receptor activity in a memorable way.

What matters more than the name

Regardless of naming convention, purity verification matters more for research validity than which shorthand a vendor uses. Every batch should have an independent Certificate of Analysis confirming identity and purity. Our guide to buying retatrutide for research lists what to verify.

Peptryn’s Retatrutide

Peptryn’s Retatrutide is HPLC-verified to 99%+ purity by an independent US lab, with a published COA for every batch in our COA Library.

If you are working with retatrutide vials, our retatrutide reconstitution guide includes a BAC water chart for 10, 30 and 60 mg vials, storage notes and how to check the lot COA.

For laboratory research use only. Not for human consumption, self-administration, or veterinary use.